Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00130270" target="_blank" >RIV/00216224:14740/23:00130270 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.phd.cz/pdf/PHD-2023_HEMATOLOGIE-2023_Program-sekce-NLZP.pdf" target="_blank" >https://www.phd.cz/pdf/PHD-2023_HEMATOLOGIE-2023_Program-sekce-NLZP.pdf</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.
Popis výsledku v původním jazyce
Acute myeloid leukemia (AML) is a malignant disease derived from the bone marrow precursors of myeloid lineage Treatment options are rather limited, primarily based on chemotherapy, and often result in disease progression Recently, venetoclax-based therapies have transformed the frontline regimens of elderly patients and patients unfit for intensive chemotherapy. Despite its promising outcomes in clinical studies, multiple resistant subclones evolved during the treatment acting as a barrier in disease regression Understanding the venetoclax-resistance mechanisms and detecting the major determinants could reveal previously unrecognized novel perspectives for therapeutic strategies to improve patients’ outcomes. Moreover, performing high-throughput screenings with clinically approved drugs could reveal novel treatment options for resistant subclones of AML.
Název v anglickém jazyce
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.
Popis výsledku anglicky
Acute myeloid leukemia (AML) is a malignant disease derived from the bone marrow precursors of myeloid lineage Treatment options are rather limited, primarily based on chemotherapy, and often result in disease progression Recently, venetoclax-based therapies have transformed the frontline regimens of elderly patients and patients unfit for intensive chemotherapy. Despite its promising outcomes in clinical studies, multiple resistant subclones evolved during the treatment acting as a barrier in disease regression Understanding the venetoclax-resistance mechanisms and detecting the major determinants could reveal previously unrecognized novel perspectives for therapeutic strategies to improve patients’ outcomes. Moreover, performing high-throughput screenings with clinically approved drugs could reveal novel treatment options for resistant subclones of AML.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů